Cargando…

CSF neurofilament light chain testing as an aid to determine treatment strategies in MS

OBJECTIVE: To evaluate the use of CSF neurofilament light chain (NfL) measurements in clinical practice as well as their effect on treatment strategies and outcomes in patients with MS. METHODS: This was an observational cohort study of patients with MS who had a CSF NfL measurement between December...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reyes, Saúl, Smets, Ide, Holden, David, Carrillo-Loza, Karina, Christmas, Tatiana, Bianchi, Lucia, Ammoscato, Francesca, Turner, Benjamin, Marta, Monica, Schmierer, Klaus, Giovannoni, Gavin, Gnanapavan, Sharmilee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455313/ https://www.ncbi.nlm.nih.gov/pubmed/32826298 http://dx.doi.org/10.1212/NXI.0000000000000880

Ejemplares similares

The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis
por: Adams, Ashok, et al.
Publicado: (2022)

The Evolution of Neurofilament Light Chain in Multiple Sclerosis
por: Ferreira-Atuesta, Carolina, et al.
Publicado: (2021)

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013)

No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation
por: Keddie, Stephen, et al.
Publicado: (2018)

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
por: Allen-Philbey, Kimberley, et al.
Publicado: (2023)

Is CSF neurofilament light chain measurement relevant for MS?
por: Matsui, Makoto
Publicado: (2020)

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
por: Ali, Liaqat, et al.
Publicado: (2020)

GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains
por: Saxena, Gauri K., et al.
Publicado: (2020)

A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann’s syndrome
por: Gnanapavan, Sharmilee, et al.
Publicado: (2014)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
por: Baker, David, et al.
Publicado: (2020)

CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Chitinase 3–like 1 and neurofilament light chain in CSF and CNS atrophy in MS
por: Schneider, Ruth, et al.
Publicado: (2020)

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
por: Jia, Yan, et al.
Publicado: (2012)

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2021)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

Detecting and predicting neutralization of alemtuzumab responses in MS
por: Saxena, Gauri, et al.
Publicado: (2020)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
por: Schmierer, K, et al.
Publicado: (2021)

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
por: Sejbaek, Tobias, et al.
Publicado: (2019)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

CSF neurofilament light chain reflects corticospinal tract degeneration in ALS
por: Menke, Ricarda A L, et al.
Publicado: (2015)

Progression in multiple sclerosis is associated with low endogenous NCAM
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
por: Puentes, Fabiola, et al.
Publicado: (2021)

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2022)

The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias
por: Abu-Rumeileh, Samir, et al.
Publicado: (2018)

Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
por: Smets, Ide
Publicado: (2023)

The potential of neurofilaments analysis using dry-blood and plasma spots
por: Lombardi, Vittoria, et al.
Publicado: (2020)

Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β
por: Lee, Paul R., et al.
Publicado: (2017)

Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease
por: Steinacker, Petra, et al.
Publicado: (2016)

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures
por: Mielke, Michelle M., et al.
Publicado: (2019)

CSF Neurofilament Light Chain Elevation Predicts ALS Severity and Progression
por: Sun, Qionghua, et al.
Publicado: (2020)

Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
por: Brodovitch, Alexandre, et al.
Publicado: (2021)

CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis
por: Chekrouni, Nora, et al.
Publicado: (2021)

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus
por: Margraf, Nils G., et al.
Publicado: (2023)

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy
por: Mahler, Christoph, et al.
Publicado: (2020)

Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension
por: Engel, Sinah, et al.
Publicado: (2023)

Author Correction: The potential of neurofilaments analysis using dry-blood and plasma spots
por: Lombardi, Vittoria, et al.
Publicado: (2020)

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
por: Khalil, M, et al.
Publicado: (2013)

CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders
por: Herbert, Megan K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rv3v12kk4htpj16c744ki6kji4